Massachusetts’ Quanttus Raises $22 Million Seed & Series A Funding

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Quanttus Raises $22 Million Seed & Series A Funding from Khosla Ventures & Matrix Partners

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Quanttus today announced that it secured $19 million in Series A financing from Khosla Ventures and Matrix Partners. This follows a previous $3 million seed financing led by Vinod Khosla of Khosla Ventures. Quanttus will use this investment to further develop breakthroughs in clinical-grade vital signs monitoring and advances in contextual analysis to create wearable technologies that, for the first time, help people proactively understand their bodies and improve their health.

“From busy professionals to those focused on living a healthy lifestyle, athletes to people living with chronic health conditions, we want to help the world get better and be better with wearable devices and digital experiences that blend with life instead of interrupting it,” said Shahid Azim, CEO and co-founder of Quanttus. “The investment and expertise of Khosla Ventures and Matrix Partners will help us further validate our vision for continuous health monitoring and bring Quanttus to market.”

Improving Health through Better Data and Personalized Insights
Our bodies provide millions of signals about our health each day, but nobody listens to them until something goes wrong. Lack of sleep and dehydration cause exhaustion. High blood pressure and diabetes can lead to cardiovascular disease. Inactivity contributes to obesity. Multiple factors contribute to our health—these variables change constantly, but people and their healthcare providers do not monitor them until something goes wrong. The world should not have to get sick in order to become healthier.

“Quanttus is pushing monitoring into many high value use cases from cardiac disease and hypertension monitoring to stress,” said Vinod Khosla of Khosla Ventures. “The team’s approach to using real-time physiological data will create powerful new tools for consumers and healthcare providers that will change how we understand our health.”

Quanttus wearable devices measure the most clinical-grade vital signs while seamlessly integrating into every part of your life from work to play to rest. Instead of simply delivering data, Quanttus delivers the most complete picture of your wellbeing and personalized insights to improve your health and to live well.

Developed by a team of experts from organizations including The Massachusetts Institute of Technology, Nike, Apple, IDEO and Massachusetts General Hospital, the Quanttus platform is comprised of two components:

Wearable technologies that can capture and analyze more than half a million vital sign data points per day
Applications that translate this data into real-time insights to help people make choices that improve their health

“There is a lot of excitement around wearables, but what makes Quanttus different is the sophistication of its technology,” added Stan Reiss, general partner at Matrix Partners. “Quanttus was developed for a specific purpose by a very serious technical and design team out of MIT. It is not a reaction to a trend but rather combines groundbreaking research with meaningful data in an elegant form factor.”

About Quanttus

Quanttus combines breakthroughs in vital signs monitoring with advances in contextual analysis to create wearable technologies that, for the first time, help people proactively understand their bodies and improve their health. For more information please visit us at www.quanttus.com.

Contact:
Quanttus
Steve Jungmann, 617-401-2645
media@quanttus.com
or
For media inquiries:
Chris Stamm or Stephanie Coleman, 617-234-4118
quanttus@waggeneredstrom.com

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC